CD49c (integrin-alpha 3, VLA-3 alpha chain, galactoprotein-B3, GAPB3, ITGA3)

Function: - heterodimer with integrin beta-1 (VLA-3) - interacts with HPS5 - isoform alpha-3A, but not isoform alpha-3B, is phosphorylated on Ser - phosphorylation increases after stimulation by phorbol 12-myristate 13-acetate Structure: - belongs to the integrin alpha chain family - contains 7 FG-GAP repeats - composed of an heavy & a light chain linked by a disulfide bond Compartment: membrane Alternative splicing: named isoforms=2 Expression: - isoform alpha-3A is widely expressed - isoform alpha-3B is expressed in brain & heart - in brain, both isoforms are exclusively expressed on vascular smooth muscle cells - in heart isoform alpha-3A is strongly expressed on vascular smooth muscle cells; isoform alpha-3B is detected only on endothelial vein cells

General

Ca+2 binding protein cluster-of-differentiation antigen; cluster designation antigen; CD antigen glycoprotein integrin-alpha

Properties

SIZE: entity length = 1066 aa MW = 119 kD COMPARTMENT: cellular membrane MOTIF: signal sequence {1-32} FG-GAP {49-94} MOTIF: N-glycosylation site {N86} cysteine residue {C94} MODIFICATION: cysteine residue {C103} cysteine residue {C103} MODIFICATION: cysteine residue {C94} N-glycosylation site {N107} FG-GAP {120-165} MOTIF: cysteine residue {C140} MODIFICATION: cysteine residue {C162} cysteine residue {C162} MODIFICATION: cysteine residue {C140} cysteine residue {C185} MODIFICATION: cysteine residue {C197} FG-GAP {195-227} MOTIF: cysteine residue {C197} MODIFICATION: cysteine residue {C185} FG-GAP {246-279} MOTIF: N-glycosylation site {N265} FG-GAP {304-345} MOTIF: Ca+2-binding site SITE: 315-323 FG-GAP {366-402} MOTIF: Ca+2-binding site SITE: 378-386 FG-GAP {426-461} MOTIF: Ca+2-binding site SITE: 439-447 cysteine residue {C485} MODIFICATION: cysteine residue {C490} cysteine residue {C490} MODIFICATION: cysteine residue {C485} cysteine residue {C496} MODIFICATION: cysteine residue {C550} N-glycosylation site {N500} N-glycosylation site {N511} cysteine residue {C550} MODIFICATION: cysteine residue {C496} N-glycosylation site {N573} N-glycosylation site {N605} cysteine residue {C615} MODIFICATION: cysteine residue {C621} cysteine residue {C621} MODIFICATION: cysteine residue {C615} N-glycosylation site {N656} cysteine residue {C694} MODIFICATION: cysteine residue {C702} N-glycosylation site {N697} cysteine residue {C702} MODIFICATION: cysteine residue {C694} N-glycosylation site {N841} cysteine residue {C846} MODIFICATION: cysteine residue {C-INTERCHAIN} N-glycosylation site {N857} cysteine residue {C911} MODIFICATION: cysteine residue {C916} cysteine residue {C916} MODIFICATION: cysteine residue {C911} N-glycosylation site {N926} N-glycosylation site {N935} N-glycosylation site {N969} transmembrane domain {992-1014} HPS5 interaction {1015-1021} MOTIF: GFFKR {1017-1021}

Database Correlations

OMIM 605025 UniProt P26006 PFAM correlations Entrez Gene 3675 Kegg hsa:3675